Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival

Marta Rossi, Greta Carioli, Martina Bonifazi, A. Zambelli, Matteo Franchi, Pasquale Lorenzo Moja, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, C. Zocchetti, Eva Vanna Lorenza Negri

Research output: Contribution to journalArticle

Abstract

The evidence on efficacy and safety of trastuzumab in metastatic breast cancers (MBC) mainly derives from randomized clinical trials. We assessed short- and long-term overall survival (OS) and cardiotoxicity in a large cohort of women with MBC treated with trastuzumab in clinical settings. Using healthcare administrative data of Lombardy (10 millions inhabitants), we identified a cohort of women receiving trastuzumab for MBC between 2006 and 2009. The cumulative risk of severe cardiac events and the OS from the first trastuzumab administration were estimated using the Kaplan-Meier method. Their predictors were assessed using Cox regression models. We found 681 trastuzumab MBC users. Thirty two (4.7%) women experienced severe cardiac adverse events. The cumulative risk increased sharply, reaching a value of 2.4% and 4.3% during the first and second year; thereafter it increased of about 1% per year. Age was a strong predictor of cardiotoxicity. The OS was 81.8%, 64.0%, 50.2%, 41.1% and 37.2% at 1, 2, 3, 4 and 5 years, respectively. Independent predictors of worse OS were: age, brain liver or lung metastasis compared to other metastasis, use of taxanes and other chemotherapies, a cardiac adverse event after trastuzumab use, and a higher time between metastasis and BC diagnoses. The incidence of cardiotoxicity among women treated with trastuzumab for HER2-positive MBC appeared higher than that reported in RCTs, particularly in elder patients. In spite of this, median survival, was, if anything, better.

Original languageEnglish
Pages (from-to)41-49
Number of pages9
JournalEuropean Journal of Cancer
Volume52
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Breast Neoplasms
Survival
Neoplasm Metastasis
Taxoids
Trastuzumab
Cardiotoxicity
Proportional Hazards Models
Randomized Controlled Trials
Delivery of Health Care
Safety
Drug Therapy
Lung
Liver
Incidence
Brain

Keywords

  • Cardiotoxicity
  • Metastatic breast cancer
  • Survival
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Trastuzumab for HER2+ metastatic breast cancer in clinical practice : Cardiotoxicity and overall survival. / Rossi, Marta; Carioli, Greta; Bonifazi, Martina; Zambelli, A.; Franchi, Matteo; Moja, Pasquale Lorenzo; Zambon, Antonella; Corrao, Giovanni; La Vecchia, Carlo; Zocchetti, C.; Negri, Eva Vanna Lorenza.

In: European Journal of Cancer, Vol. 52, 01.01.2016, p. 41-49.

Research output: Contribution to journalArticle

Rossi, M, Carioli, G, Bonifazi, M, Zambelli, A, Franchi, M, Moja, PL, Zambon, A, Corrao, G, La Vecchia, C, Zocchetti, C & Negri, EVL 2016, 'Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival', European Journal of Cancer, vol. 52, pp. 41-49. https://doi.org/10.1016/j.ejca.2015.09.012
Rossi, Marta ; Carioli, Greta ; Bonifazi, Martina ; Zambelli, A. ; Franchi, Matteo ; Moja, Pasquale Lorenzo ; Zambon, Antonella ; Corrao, Giovanni ; La Vecchia, Carlo ; Zocchetti, C. ; Negri, Eva Vanna Lorenza. / Trastuzumab for HER2+ metastatic breast cancer in clinical practice : Cardiotoxicity and overall survival. In: European Journal of Cancer. 2016 ; Vol. 52. pp. 41-49.
@article{c541e2e3bd4c4bbaa1b92adb18c9184c,
title = "Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival",
abstract = "The evidence on efficacy and safety of trastuzumab in metastatic breast cancers (MBC) mainly derives from randomized clinical trials. We assessed short- and long-term overall survival (OS) and cardiotoxicity in a large cohort of women with MBC treated with trastuzumab in clinical settings. Using healthcare administrative data of Lombardy (10 millions inhabitants), we identified a cohort of women receiving trastuzumab for MBC between 2006 and 2009. The cumulative risk of severe cardiac events and the OS from the first trastuzumab administration were estimated using the Kaplan-Meier method. Their predictors were assessed using Cox regression models. We found 681 trastuzumab MBC users. Thirty two (4.7{\%}) women experienced severe cardiac adverse events. The cumulative risk increased sharply, reaching a value of 2.4{\%} and 4.3{\%} during the first and second year; thereafter it increased of about 1{\%} per year. Age was a strong predictor of cardiotoxicity. The OS was 81.8{\%}, 64.0{\%}, 50.2{\%}, 41.1{\%} and 37.2{\%} at 1, 2, 3, 4 and 5 years, respectively. Independent predictors of worse OS were: age, brain liver or lung metastasis compared to other metastasis, use of taxanes and other chemotherapies, a cardiac adverse event after trastuzumab use, and a higher time between metastasis and BC diagnoses. The incidence of cardiotoxicity among women treated with trastuzumab for HER2-positive MBC appeared higher than that reported in RCTs, particularly in elder patients. In spite of this, median survival, was, if anything, better.",
keywords = "Cardiotoxicity, Metastatic breast cancer, Survival, Trastuzumab",
author = "Marta Rossi and Greta Carioli and Martina Bonifazi and A. Zambelli and Matteo Franchi and Moja, {Pasquale Lorenzo} and Antonella Zambon and Giovanni Corrao and {La Vecchia}, Carlo and C. Zocchetti and Negri, {Eva Vanna Lorenza}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2015.09.012",
language = "English",
volume = "52",
pages = "41--49",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Trastuzumab for HER2+ metastatic breast cancer in clinical practice

T2 - Cardiotoxicity and overall survival

AU - Rossi, Marta

AU - Carioli, Greta

AU - Bonifazi, Martina

AU - Zambelli, A.

AU - Franchi, Matteo

AU - Moja, Pasquale Lorenzo

AU - Zambon, Antonella

AU - Corrao, Giovanni

AU - La Vecchia, Carlo

AU - Zocchetti, C.

AU - Negri, Eva Vanna Lorenza

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The evidence on efficacy and safety of trastuzumab in metastatic breast cancers (MBC) mainly derives from randomized clinical trials. We assessed short- and long-term overall survival (OS) and cardiotoxicity in a large cohort of women with MBC treated with trastuzumab in clinical settings. Using healthcare administrative data of Lombardy (10 millions inhabitants), we identified a cohort of women receiving trastuzumab for MBC between 2006 and 2009. The cumulative risk of severe cardiac events and the OS from the first trastuzumab administration were estimated using the Kaplan-Meier method. Their predictors were assessed using Cox regression models. We found 681 trastuzumab MBC users. Thirty two (4.7%) women experienced severe cardiac adverse events. The cumulative risk increased sharply, reaching a value of 2.4% and 4.3% during the first and second year; thereafter it increased of about 1% per year. Age was a strong predictor of cardiotoxicity. The OS was 81.8%, 64.0%, 50.2%, 41.1% and 37.2% at 1, 2, 3, 4 and 5 years, respectively. Independent predictors of worse OS were: age, brain liver or lung metastasis compared to other metastasis, use of taxanes and other chemotherapies, a cardiac adverse event after trastuzumab use, and a higher time between metastasis and BC diagnoses. The incidence of cardiotoxicity among women treated with trastuzumab for HER2-positive MBC appeared higher than that reported in RCTs, particularly in elder patients. In spite of this, median survival, was, if anything, better.

AB - The evidence on efficacy and safety of trastuzumab in metastatic breast cancers (MBC) mainly derives from randomized clinical trials. We assessed short- and long-term overall survival (OS) and cardiotoxicity in a large cohort of women with MBC treated with trastuzumab in clinical settings. Using healthcare administrative data of Lombardy (10 millions inhabitants), we identified a cohort of women receiving trastuzumab for MBC between 2006 and 2009. The cumulative risk of severe cardiac events and the OS from the first trastuzumab administration were estimated using the Kaplan-Meier method. Their predictors were assessed using Cox regression models. We found 681 trastuzumab MBC users. Thirty two (4.7%) women experienced severe cardiac adverse events. The cumulative risk increased sharply, reaching a value of 2.4% and 4.3% during the first and second year; thereafter it increased of about 1% per year. Age was a strong predictor of cardiotoxicity. The OS was 81.8%, 64.0%, 50.2%, 41.1% and 37.2% at 1, 2, 3, 4 and 5 years, respectively. Independent predictors of worse OS were: age, brain liver or lung metastasis compared to other metastasis, use of taxanes and other chemotherapies, a cardiac adverse event after trastuzumab use, and a higher time between metastasis and BC diagnoses. The incidence of cardiotoxicity among women treated with trastuzumab for HER2-positive MBC appeared higher than that reported in RCTs, particularly in elder patients. In spite of this, median survival, was, if anything, better.

KW - Cardiotoxicity

KW - Metastatic breast cancer

KW - Survival

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84948394457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948394457&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.09.012

DO - 10.1016/j.ejca.2015.09.012

M3 - Article

VL - 52

SP - 41

EP - 49

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -